Celltrion US adalimumab-aaty biosimilar pricing

The US unit of South Korea’s Celltrion (Kosdaq: 068270) announced that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to Humira (adalimumab), is now available at a low wholesale acquisition cost (WAC).

Adalimumab-aaty will be priced as WAC list price at an 85% discount to the current WAC list price of AbbVie’s blockbuster drug Humira. Adalimumab-aaty is also available from Celltrion USA under the brand name Yuflyma, which launched in July 2023 and is available at a 5% discount to the current WAC list price of Humira.

Adalimumab-aaty is approved for the treatment of eight conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.